Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Name: Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD
Start: 2021-09-13T15:00:00-05:00
End: 2021-09-13T16:00:00-05:00

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

HealthTree Podcast for AML

Sep 13, 2021 / 03:00PM CDT

Listen to Podcast

Event Description

In this HealthTree Radio for AML show, Dr. Gabriel Mannis talks about treatment options for older adults with AML. He reviews his open clinical trial looking at what could be the first all-oral treatment for newly diagnosed older patients. The combination of venetoclax and decitabine with cedazuridine (ASTX727 or Inqovi) would provide older adults with AML and those who cannot tolerate standard intensive chemotherapy a much-needed alternative treatment option.

To listen to the recording or read the transcript of this past radio show,

click here

Schedule & Agenda

Welcome

03:00PM

Welcome, announcements and introduction

03:00PM

Welcome

Welcome, announcements and introduction

Interview

03:05PM

Dr. Mannis answers questions about his open clinical trial: Pharmacokinetics, Safety, and Efficacy of Decitabine/Cedazuridine (ASTX727) in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

03:05PM

Interview

Dr. Mannis answers questions about his open clinical trial: Pharmacokinetics, Safety, and Efficacy of Decitabine/Cedazuridine (ASTX727) in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Q&A

03:50PM

Audience is able to call in to the radio show (515) 602-9728 to ask Dr. Mannis questions.

03:50PM

Q&A

Audience is able to call in to the radio show (515) 602-9728 to ask Dr. Mannis questions.

Speakers & Moderators

Gabriel Mannis, MD

Palo Alto, CA

Dr. Mannis is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine, and Medical Director of Stanford’s Inpatient Leukemia Service. He specializes in the treatment of acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. As a clinical scientist, Dr. Mannis divides his time between caring for patients, teaching trainees, and researching novel therapies for AML and MDS.

Read Bio

Katie Braswell

Dallas, Texas

Katie joined the HealthTree Foundation as the Community Director for AML in 2021. She is a registered dietitian who previously worked at the VA hospital in Dallas, Texas where she coached veterans with blood cancer on how to use nutrition to improve their treatment outcomes and minimize cancer-related side effects. Katie is passionate about health education and patient empowerment. In her spare time, she loves to experiment with new recipes in the kitchen, spend time running outdoors, and travel to new places.

Read Bio